bioAffinity Technologies Inc
bioAffinity Technologies Inc (BIAF) is a very small-cap company operating in the medical diagnostics space. With a market capitalisation of around $12.73m, it is typically classed as an early-stage, speculative investment: revenues may be limited, operations can depend on research and development, regulatory approvals and partnerships, and the stock can be thinly traded. Key catalysts for value can include clinical data releases, regulatory decisions or licensing deals, while main risks include funding needs, development setbacks and market liquidity. Because of its size and stage, the share price can be highly volatile and subject to dilution if new capital is raised. This summary is for general educational purposes only and not personal financial advice — investors should read the company’s filings, check recent financial reports and consider seeking regulated advice as investments can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping bioAffinity Technologies stock as it may not significantly rise or fall.
Financial Health
bioAffinity Technologies is generating steady revenue and cash flow, indicating a positive financial outlook.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BIAF
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage catalysts
Clinical data, regulatory decisions and partnership news can materially move the share price, though outcomes are uncertain and volatility can be high.
R&D and funding
Progress in diagnostics development could unlock value but typically requires ongoing funding; capital raises can dilute existing shareholders.
Liquidity and size
A small market capitalisation and thin trading can amplify price swings and make buying or selling large positions harder—consider diversification.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
